Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:00 ET | Source: Lyell Immunopharma, Inc

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for...
September 03, 2025 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving...
September 02, 2025 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing...
August 12, 2025 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the...
July 25, 2025 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with...
June 23, 2025 17:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with...
June 17, 2025 06:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with...
June 09, 2025 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary,...
June 04, 2025 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for...
May 13, 2025 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or...